Polysubstance use before and during treatment with medication for opioid use disorder: Prevalence and association with treatment outcomes
- PMID: 35773113
- PMCID: PMC10012431
- DOI: 10.1016/j.jsat.2022.108830
Polysubstance use before and during treatment with medication for opioid use disorder: Prevalence and association with treatment outcomes
Abstract
Objective: Polysubstance use may complicate treatment outcomes for individuals who use opioids. This research aimed to examine the prevalence of polysubstance use in an opioid use disorder treatment trial population and polysubstance use's association with opioid relapse and craving.
Methods: This study is a secondary data analysis of individuals with opioid use disorder who received at least one dose of medication (n = 474) as part of a 24-week, multi-site, open label, randomized Clinical Trials Network study (CTN0051, X:BOT) comparing the effectiveness of extended-release naltrexone versus buprenorphine. Models examined pretreatment polysubstance use and polysubstance use during the initial 4 weeks of treatment on outcomes of relapse by week 24 of the treatment trial and opioid craving.
Results: Polysubstance use was generally not associated with treatment outcomes of opioid relapse and craving. Proportion of days of pretreatment sedative use was associated with increased likelihood of opioid relapse (OR: 1.01, 95 % CI: 1.00-1.02). Proportion of days of cocaine use during the initial 4 weeks of treatment was associated with increased likelihood of opioid relapse (OR: 1.05, 95 % CI: 1.01-1.09) but this effect was no longer significant once the potential of confounding by opioid use was considered. Sedative use during initial 4 weeks of treatment was associated with increased opioid craving (b: 0.77, 95 % CI: 0.01-1.52). The study found no other significant relationships.
Conclusions: In the current study population, polysubstance use was only marginally associated with 24-week treatment outcomes.
Keywords: Buprenorphine; Naltrexone; Opioid use disorder; Polysubstance use; Treatment.
Copyright © 2022 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of competing interest Dr. Rotrosen is and has been, a Principal Investigator or a co-Investigator on studies for which support in the form of donated or discounted medication and/or funds has been, or will be, provided by Alkermes, Inc. (Vivitrol, extended-release injectable naltrexone), Indivior, Inc. (formerly Reckitt-Benckiser; Suboxone, buprenorphine/naloxone combination), and Braeburn Pharmaceuticals, Inc. (extended-release injectable buprenorphine); and digital therapeutics from Pear Therapeutics (smartphone apps ReSET and ReSET-O), CHESS Health (Connections smartphone app), and Data Cubed (smartphone apps SOAR and mSAPPORT). None of this support has gone, or will go, directly to him, rather to either NYU, or to NIDA/NIH, or to NIDA's contractor Emmes, Inc. Dr. Rotrosen recently served in a non-paid capacity as a member of an Alkermes study Steering Committee. He has no relevant equity, intellectual property, paid consulting, travel or other arrangements with any of these entities. Dr. McNeely declares intellectual property interests in the Substance Use Screening and Intervention Tool (SUSIT), which is in the public domain and unrelated to this work. Dr. Lee has received in-kind study drug for recent and current NIDA-funded trials from Alkermes Inc. and Indivior PLC. Dr. Lee has received a recent investigator sponsored study grant from Indivior PLC. Dr. Lee is a science advisor to Oar Health LLC. Dr. Nunes received medication for studies from Alkermes (Vivitrol), Indivior (Suboxone, Sublocade), and Braeburn (CAM2038/Brixadi), received technology for studies from Pear Therapeutics, CHESS Health, served as an unpaid consultant to Alkermes, Braeburn/Camurus, Pear Therapeutics, and has been an investigator on studies by Braeburn Pharmaceuticals (CAM2038/Brixadi). Dr. Tofighi is a consultant to Oar Health LLC.
Figures
Similar articles
-
Naturalistic follow-up after a trial of medications for opioid use disorder: Medication status, opioid use, and relapse.J Subst Abuse Treat. 2021 Dec;131:108447. doi: 10.1016/j.jsat.2021.108447. Epub 2021 Apr 30. J Subst Abuse Treat. 2021. PMID: 34098301 Free PMC article. Clinical Trial.
-
Patient Characteristics Associated with Opioid Abstinence after Participation in a Trial of Buprenorphine versus Injectable Naltrexone.Subst Use Misuse. 2022;57(11):1732-1742. doi: 10.1080/10826084.2022.2112230. Epub 2022 Aug 17. Subst Use Misuse. 2022. PMID: 35975917 Free PMC article. Clinical Trial.
-
An alternative analysis of illicit opioid use during treatment in a randomized trial of extended-release naltrexone versus buprenorphine-naloxone: A per-protocol and completers analysis.Drug Alcohol Depend. 2021 Feb 1;219:108422. doi: 10.1016/j.drugalcdep.2020.108422. Epub 2020 Dec 9. Drug Alcohol Depend. 2021. PMID: 33352487 Free PMC article. Clinical Trial.
-
Acceptability and efficacy of naltrexone for criminal justice-involved individuals with opioid use disorder: a systematic review and meta-analysis.Addiction. 2020 Aug;115(8):1413-1425. doi: 10.1111/add.14946. Epub 2020 Jan 17. Addiction. 2020. PMID: 31863669
-
Extended-release injectable naltrexone for opioid use disorder: a systematic review.Addiction. 2018 Jul;113(7):1188-1209. doi: 10.1111/add.14180. Epub 2018 Mar 24. Addiction. 2018. PMID: 29396985 Free PMC article.
Cited by
-
Prenatal substance use and mental health comorbidities predict continued use.Psychol Addict Behav. 2025 May;39(3):301-310. doi: 10.1037/adb0001017. Epub 2024 Jul 18. Psychol Addict Behav. 2025. PMID: 39023997
-
Effects of randomization to buprenorphine or naltrexone for OUD on cannabis use outcomes: A secondary analysis of the X:BOT trial.Drug Alcohol Depend. 2025 Mar 1;268:112550. doi: 10.1016/j.drugalcdep.2025.112550. Epub 2025 Jan 18. Drug Alcohol Depend. 2025. PMID: 39892089 Clinical Trial.
-
Drug use patterns and factors related to the use and discontinuation of medications for opioid use disorder in the age of fentanyl: findings from a mixed-methods study of people who use drugs.Subst Abuse Treat Prev Policy. 2023 May 22;18(1):30. doi: 10.1186/s13011-023-00538-x. Subst Abuse Treat Prev Policy. 2023. PMID: 37217975 Free PMC article.
-
The Emergence of the Old Drug Captagon as a New Illicit Drug: A Narrative Review.Cureus. 2024 Feb 27;16(2):e55053. doi: 10.7759/cureus.55053. eCollection 2024 Feb. Cureus. 2024. PMID: 38550445 Free PMC article. Review.
-
Measuring time in buprenorphine treatment stages among people with HIV and opioid use disorder by retention definition and its association with cocaine and hazardous alcohol use.Addict Sci Clin Pract. 2023 Sep 2;18(1):51. doi: 10.1186/s13722-023-00408-8. Addict Sci Clin Pract. 2023. PMID: 37660116 Free PMC article.
References
-
- Betts KS, Chan G, McIlwraith F, Dietze P, Whittaker E, Burns L, & Alati R.(2016). Differences in polysubstance use patterns and drug-related outcomes between people who inject drugs receiving and not receiving opioid substitution therapies. Addiction, 111(7), 1214–1223. 10.1111/add.13339 - DOI - PubMed
-
- Blondino CT, Gormley MA, Taylor DSDH, Lowery E, Clifford JS, Burkart B, Graves WC, Lu J, & Prom-Wormley EC (2020). The association of co-occurring substance use and the effectiveness of opiate treatment programs by intervention type: A systematic review. Epidemiologic Reviews, 42(1), 57–78. 10.1093/epirev/mxaa005 - DOI - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- UG1 DA015831/DA/NIDA NIH HHS/United States
- U10 DA013046/DA/NIDA NIH HHS/United States
- K23 DA042140/DA/NIDA NIH HHS/United States
- UG1 DA013714/DA/NIDA NIH HHS/United States
- UG1 DA013034/DA/NIDA NIH HHS/United States
- R25 DA037190/DA/NIDA NIH HHS/United States
- U10 DA015833/DA/NIDA NIH HHS/United States
- U10 DA013720/DA/NIDA NIH HHS/United States
- U10 DA015831/DA/NIDA NIH HHS/United States
- U10 DA013035/DA/NIDA NIH HHS/United States
- T32 HS026120/HS/AHRQ HHS/United States
- HHSN271201200017C/DA/NIDA NIH HHS/United States
- UG1 DA013732/DA/NIDA NIH HHS/United States
- U10 DA013714/DA/NIDA NIH HHS/United States
- UG1 DA013720/DA/NIDA NIH HHS/United States
- K01 DA053435/DA/NIDA NIH HHS/United States
- UG1 DA013035/DA/NIDA NIH HHS/United States
- HHSN271201500065C/DA/NIDA NIH HHS/United States
- U10 DA013732/DA/NIDA NIH HHS/United States
- U10 DA013045/DA/NIDA NIH HHS/United States
- U10 DA013034/DA/NIDA NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical